Literature DB >> 16338387

Overview of approaches for screening for ubiquitin ligase inhibitors.

Yi Sun1.   

Abstract

E3 ubiquitin ligases are a large family of proteins that, together with ubiquitin-activating enzyme E1 and ubiquitin-conjugating enzyme E2, catalyze the ubiquitination of a variety of protein substrates for targeted degradation by means of the 26S proteasome. Because the turnover of many proteins involves targeted ubiquitination and degradation, E3 ubiquitin ligases, therefore, regulate almost every aspect of eukaryotic cellular functions or biological processes. Accumulated evidence in the past few years has suggested that a subset of E3 ubiquitin ligases that regulates the turnover of tumor suppressors and cell cycle regulators could be promising targets for mechanism-driven cancer drug discovery. Thus, it is highly desirable to optimize the methods of high-throughput screening (HTS) for specific inhibitors of these E3 ubiquitin ligases. Here I will give an overview of several approaches used for HTS for ubiquitin ligase inhibitors with a main focus on assay principles, applications, and the pros and cons of each approach. Experimental details for many of these assays can be found in other chapters in this volume.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16338387     DOI: 10.1016/S0076-6879(05)99043-5

Source DB:  PubMed          Journal:  Methods Enzymol        ISSN: 0076-6879            Impact factor:   1.600


  13 in total

1.  Radiosensitization of human pancreatic cancer cells by MLN4924, an investigational NEDD8-activating enzyme inhibitor.

Authors:  Dongping Wei; Hua Li; Jie Yu; Jonathan T Sebolt; Lili Zhao; Theodore S Lawrence; Peter G Smith; Meredith A Morgan; Yi Sun
Journal:  Cancer Res       Date:  2011-11-09       Impact factor: 12.701

2.  Induction of p21-dependent senescence by an NAE inhibitor, MLN4924, as a mechanism of growth suppression.

Authors:  Lijun Jia; Hua Li; Yi Sun
Journal:  Neoplasia       Date:  2011-06       Impact factor: 5.715

3.  A cell-based high-throughput screening method based on a ubiquitin-reference technique for identifying modulators of E3 ligases.

Authors:  Maoyuan Tian; Taoling Zeng; Mingdong Liu; Shang Han; Huayue Lin; Qi Lin; Li Li; Tingting Jiang; Gao Li; Hong Lin; Ting Zhang; Qiaofeng Kang; Xianming Deng; Hong-Rui Wang
Journal:  J Biol Chem       Date:  2018-12-26       Impact factor: 5.157

4.  TR-FRET-based high-throughput screening assay for identification of UBC13 inhibitors.

Authors:  Charitha Madiraju; Kate Welsh; Michael P Cuddy; Paulo H Godoi; Ian Pass; Tram Ngo; Stefan Vasile; Eduard A Sergienko; Paul Diaz; Shu-Ichi Matsuzawa; John C Reed
Journal:  J Biomol Screen       Date:  2011-10-27

Review 5.  E3 ubiquitin ligases as cancer targets and biomarkers.

Authors:  Yi Sun
Journal:  Neoplasia       Date:  2006-08       Impact factor: 5.715

6.  Small RING Finger Proteins RBX1 and RBX2 of SCF E3 Ubiquitin Ligases: The Role in Cancer and as Cancer Targets.

Authors:  Dongping Wei; Yi Sun
Journal:  Genes Cancer       Date:  2010-07

Review 7.  SCF E3 ubiquitin ligases as anticancer targets.

Authors:  L Jia; Y Sun
Journal:  Curr Cancer Drug Targets       Date:  2011-03       Impact factor: 3.428

Review 8.  Ubiquitination Regulators Discovered by Virtual Screening for the Treatment of Cancer.

Authors:  Ying-Qi Song; Chun Wu; Ke-Jia Wu; Quan-Bin Han; Xiang-Min Miao; Dik-Lung Ma; Chung-Hang Leung
Journal:  Front Cell Dev Biol       Date:  2021-05-12

Review 9.  The role of PML ubiquitination in human malignancies.

Authors:  Ruey-Hwa Chen; Yu-Ru Lee; Wei-Chien Yuan
Journal:  J Biomed Sci       Date:  2012-08-30       Impact factor: 8.410

10.  The p21-dependent radiosensitization of human breast cancer cells by MLN4924, an investigational inhibitor of NEDD8 activating enzyme.

Authors:  Dong Yang; Mingjia Tan; Gongxian Wang; Yi Sun
Journal:  PLoS One       Date:  2012-03-22       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.